ATARA BIOTHERAPEUTICS

atara-biotherapeutics-logo

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Ataraโ€™s technology platform leverages research collaborations with leading academic institutions with the Companyโ€™s scientific, clinical, regulatory, and manufacturing expertise. Ataraโ€™s pipeline includes tab-celยฎ (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associ... ated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

#SimilarOrganizations #People #Financial #Event #Website #More

ATARA BIOTHERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Oncology Therapeutics

Founded:
2012-01-01

Address:
South San Francisco, California, United States

Country:
United States

Website Url:
http://www.atarabio.com

Total Employee:
251+

Status:
Active

Contact:
+1 650 278 8930

Email Addresses:
[email protected]

Total Funding:
499.82 M USD

Technology used in webpage:
Domain Not Resolving LetsEncrypt HSTS JsDelivr U.S. Server Location Microsoft CloudFront PostalAddress Schema Microsoft Azure Amazon California Region


Similar Organizations

avstera-therapeutics-logo

Avstera Therapeutics

Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.

cero-therapeutics-logo

Cero Therapeutics

CERo Therapeutics, Inc. is a new cellular immunotherapy company.

geneos-therapeutics-logo

Geneos Therapeutics

Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.

peroxitech-therapeutics-logo

Peroxitech Therapeutics

Peroxitech Therapeutics operates as a biopharmaceutical company.

pinpoint-therapeutics-logo

Pinpoint Therapeutics

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.

scout-bio-logo

Scout Bio

Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.

tmunity-therapeutics-logo

Tmunity Therapeutics

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells

verismo-therapeutics-logo

Verismo Therapeutics

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.


Current Advisors List

beth-seidenberg_image

Beth Seidenberg Member of the Board of Directors @ Atara Biotherapeutics
Board_member

ameet-mallik_image

Ameet Mallik Board Member @ Atara Biotherapeutics
Board_member
2021-08-01

matthew-fust_image

Matthew Fust Audit Committee Chair @ Atara Biotherapeutics
Board_member

carol-gallagher_image

Carol Gallagher Executive Chair @ Atara Biotherapeutics
Board_member

Current Employees Featured

charlene-banard_image

Charlene Banard
Charlene Banard CTO @ Atara Biotherapeutics
CTO
2022-04-01

jill-henrich_image

Jill Henrich
Jill Henrich SVP, Global Regulatory Affairs @ Atara Biotherapeutics
SVP, Global Regulatory Affairs
2020-09-01

maclovia-zelaya_image

Maclovia Zelaya
Maclovia Zelaya Executive Assistant to Chief Executive Officer @ Atara Biotherapeutics
Executive Assistant to Chief Executive Officer
2017-12-01

aj-joshi_image

AJ Joshi
AJ Joshi Head of Clinical Development and Chief Medical Officer @ Atara Biotherapeutics
Head of Clinical Development and Chief Medical Officer
2018-09-01

utpal-koppikar_image

Utpal Koppikar
Utpal Koppikar Chief Financial Officer & Senior Vice President @ Atara Biotherapeutics
Chief Financial Officer & Senior Vice President

christopher-haqq_image

Christopher Haqq
Christopher Haqq Executive Vice President of Research & Development & Chief Scientific Officer @ Atara Biotherapeutics
Executive Vice President of Research & Development & Chief Scientific Officer
2016-10-01

joe-newell_image

Joe Newell
Joe Newell Chief Operations Officer @ Atara Biotherapeutics
Chief Operations Officer

steve-bertram_image

Steve Bertram
Steve Bertram SVP, Chief People Officer @ Atara Biotherapeutics
SVP, Chief People Officer

k-amar-murugan_image

K. Amar Murugan
K. Amar Murugan General Counsel @ Atara Biotherapeutics
General Counsel

pascal-touchon_image

Pascal Touchon
Pascal Touchon President and CEO/ Member of the Board of Directors @ Atara Biotherapeutics
President and CEO/ Member of the Board of Directors
2019-06-01

Founder


isaac-ciechanover_image

Isaac Ciechanover

Stock Details


Company's stock symbol is NASDAQ:ATRA

Investors List

domain-associates_image

Domain Associates

Domain Associates investment in Series B - Atara Biotherapeutics

dag-ventures_image

DAG Ventures

DAG Ventures investment in Series B - Atara Biotherapeutics

celgene_image

Celgene

Celgene investment in Series B - Atara Biotherapeutics

alexandria-venture_image

Alexandria

Alexandria investment in Series B - Atara Biotherapeutics

kleiner-perkins-caufield-byers_image

Kleiner Perkins

Kleiner Perkins investment in Series B - Atara Biotherapeutics

ecor1-capital_image

EcoR1 Capital

EcoR1 Capital investment in Series B - Atara Biotherapeutics

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series B - Atara Biotherapeutics

domain-associates_image

Domain Associates

Domain Associates investment in Series B - Atara Biotherapeutics

kleiner-perkins-caufield-byers_image

Kleiner Perkins

Kleiner Perkins investment in Series B - Atara Biotherapeutics

alexandria-venture_image

Alexandria

Alexandria investment in Series B - Atara Biotherapeutics

Official Site Inspections

http://www.atarabio.com Semrush global rank: 3.49 M Semrush visits lastest month: 3.75 K

  • Host name: 141.193.213.11
  • IP address: 141.193.213.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Atara Biotherapeutics"

Atara Biotherapeutics (ATRA)

Nov 12, 2024 Investor and Media Relations. Amber Daugherty Sr Director, Strategy and Operations T: (805) 696-2279 [email protected]See details»

Atara Biotherapeutics - LinkedIn

Atara Biotherapeutics | 37,817 followers on LinkedIn. Pioneering off-the-shelf, allogeneic T-cell immunotherapies | Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company ...See details»

Atara Biotherapeutics - Crunchbase Company Profile

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with โ€ฆSee details»

Atara Biotherapeutics - Overview, News & Similar companies

Atara Biotherapeutics has announced that Dan Maziasz, Chief Business Officer, has left the organization to join Kyverna Therapeutics as Chief Business Officer. ... Phone number: (805) โ€ฆSee details»

Atara Bio Company Profile | Management and Employees List

SQL International Organization for Standardization . Lua PUC-Rio . HTML Web Hypertext Application Technology Working Group . CSS World Wide Web Consortium . Enterprise โ€ฆSee details»

Atara Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Explore Atara Biotherapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 232 news, and 37 literature, Disease Domain:Neoplasms, Immune System โ€ฆSee details»

Company Profile for Atara Biotherapeutics, Inc. - BioSpace

Apr 2, 2020 Company: Atara Biotherapeutics, Inc. Headquarters Address: 611 Gateway Blvd. Suite 900. South San Francisco, CA 94080. Main Telephone: (650) 278-8930. Website:See details»

Atara Biotherapeutics Announces First Quarter Financial Results โ€ฆ

2 days ago Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...See details»

T-Cell Immunotherapy Technology Platform โ€ฆ

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.See details»

Working At Atara Biotherapeutics: Company Overview and Culture โ€ฆ

Mar 14, 2024 Organization Type. Public. Social Media. Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel โ€ฆSee details»

Technology - Atara Biotherapeutics

Through our leading-edge ARC research and development facility in Southern California; Fitzsimons Process Development facility in Denver, Colorado; and Contract Manufacturing โ€ฆSee details»

Governance :: Atara Biotherapeutics (ATRA)

Board Members Audit Human Capital Nominating and Corporate Governance Research and Development; Carol Gallagher, Pharm.D.See details»

Atara Biotherapeutics Announces $36 Million Registered Direct โ€ฆ

Sep 3, 2024 Investor and Media Relations: Jason Awe, Ph.D. Head of Corporate Communications & Investor Relations (805) 217-2287 [email protected] Social Media โ€ฆSee details»

Responsibility - Atara Biotherapeutics

However, as a clinical stage biotechnology company pushing the boundaries of science, we recognize there is always more that can be done. We actively seek ways to ensure diversity, โ€ฆSee details»

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO

May 5, 2025 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...See details»

News & Events :: Atara Biotherapeutics (ATRA)

Mar 7, 2025 View All Presentations. Email Alerts. Sign up for email alerts for Press Releases & SEC Filings. Sign UpSee details»

Developing Novel T-Cell Immunotherapy Treatments - Atara โ€ฆ

Our clinical studies evaluate the potential of our investigational treatments in a well-defined patient population with eligibility criteria that allow for appropriate assessment of safety and clinical โ€ฆSee details»

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO ...

May 5, 2025 For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn. About tabelecleucel Tabelecleucel is an off-the-shelf allogeneic cell therapy composed of EBV โ€ฆSee details»

Atara Biotherapeutics Announces $36 Million Registered Direct โ€ฆ

Sep 3, 2024 Led by Existing Top Institutional Investors With Participation From a New Strategic Investor. Well Positioned To Execute on Tab-cel ® U.S. BLA Approval and Advancement of โ€ฆSee details»

Tab-cel - Atara Biotherapeutics

An innovative approach for at-risk transplant patients. Tabelecleucel (tab-cel ®) is being developed for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease โ€ฆSee details»

linkstock.net © 2022. All rights reserved